ROS1 and sarcomatoid carcinoma: The oncogenic potential of TPM3‐ROS1 is further supported by its role in spindle cell carcinoma (SpCC) of the lung, where targeted therapy with crizotinib, a ROS1 inhibitor, has shown clinical efficacy.